Chiesi Sues Aurobindo to Block Copies of Kengreal Anti-Clot Drug

Chiesi Farmaceutici SpA alleges that a generic version of Kengreal proposed by Aurobindo Pharma Ltd.’s Eugia units infringes seven patents for the injectable clot inhibitor.

Aurobindo said in a Nov. 21 letter to Chiesi that it had filed an application with the US Food and Drug Administration seeking approval of its Kengreal copy before seven of the eight patents listed for Kengreal in the agency’s registry of approved drugs, the Orange Book, expire, according to a complaint filed Wednesday in the US District Court for the District of New Jersey.

Parma, Italy-based Chiesi and its Chiesi USA Inc. unit, both ...